Literature DB >> 29017062

Integration of the TGx-28.65 genomic biomarker with the flow cytometry micronucleus test to assess the genotoxicity of disperse orange and 1,2,4-benzenetriol in human TK6 cells.

Julie K Buick1, Andrew Williams1, Byron Kuo1, John W Wills1, Carol D Swartz2, Leslie Recio2, Heng-Hong Li3, Albert J Fornace3, Jiri Aubrecht4, Carole L Yauk5.   

Abstract

In vitro gene expression signatures to predict toxicological responses can provide mechanistic context for regulatory testing. We previously developed the TGx-28.65 genomic biomarker from a database of gene expression profiles derived from human TK6 cells exposed to 28 well-known compounds. The biomarker comprises 65 genes that can classify chemicals as DNA damaging or non-DNA damaging. In this study, we applied the TGx-28.65 genomic biomarker in parallel with the in vitro micronucleus (MN) assay to determine if two chemicals of regulatory interest at Health Canada, disperse orange (DO: the orange azo dye 3-[[4-[(4-Nitrophenyl)azo]phenyl] benzylamino]propanenitrile) and 1,2,4-benzenetriol (BT: a metabolite of benzene) are genotoxic or non-genotoxic. Both chemicals caused dose-dependent declines in relative survival and increases in apoptosis. A strong significant increase in MN induction was observed for all concentrations of BT; the top two concentrations of DO also caused a statistically significant increase in MN, but these increases were <2-fold above controls. TGx-28.65 analysis classified BT as genotoxic at all three concentrations and DO as genotoxic at the mid and high concentrations. Thus, although DO only caused a small increase in MN, this response was sufficient to induce a cellular DNA damage response. Benchmark dose modeling confirmed that BT is much more potent than DO. The results strongly suggest that follow-up work is required to assess whether DO and BT are also genotoxic in vivo. This is particularly important for DO, which may require metabolic activation by bacterial gut flora to fully induce its genotoxic potential. Our previously published data and this proof of concept study suggest that the TGx-28.65 genomic biomarker has the potential to add significant value to existing approaches used to assess genotoxicity. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Gene expression microarray; Genetic toxicology; Human health risk assessment; Metabolic activation; Micronucleus; TGx-28.65 genomic biomarker; TGx-DDI genomic biomarker

Mesh:

Substances:

Year:  2017        PMID: 29017062     DOI: 10.1016/j.mrfmmm.2017.09.002

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  3 in total

1.  Development and validation of a high-throughput transcriptomic biomarker to address 21st century genetic toxicology needs.

Authors:  Heng-Hong Li; Renxiang Chen; Daniel R Hyduke; Andrew Williams; Roland Frötschl; Heidrun Ellinger-Ziegelbauer; Raegan O'Lone; Carole L Yauk; Jiri Aubrecht; Albert J Fornace
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

2.  Integrated Genotoxicity Testing of three anti-infective drugs using the TGx-DDI transcriptomic biomarker and high-throughput CometChip® assay in TK6 cells.

Authors:  Julie K Buick; Andrea Rowan-Carroll; Rémi Gagné; Andrew Williams; Renxiang Chen; Heng-Hong Li; Albert J Fornace; Christy Chao; Bevin P Engelward; Roland Frötschl; Heidrun Ellinger-Ziegelbauer; Syril D Pettit; Jiri Aubrecht; Carole L Yauk
Journal:  Front Toxicol       Date:  2022-09-23

3.  Flow cytometric micronucleus assay and TGx-DDI transcriptomic biomarker analysis of ten genotoxic and non-genotoxic chemicals in human HepaRG™ cells.

Authors:  Julie K Buick; Andrew Williams; Rémi Gagné; Carol D Swartz; Leslie Recio; Stephen S Ferguson; Carole L Yauk
Journal:  Genes Environ       Date:  2020-02-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.